Biotest AG (BTTAY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Biotest AG (BTTAY) es una empresa del sector Healthcare valorada en 0. Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 15 mar 2026Biotest AG (BTTAY) Resumen de Asistencia Médica y Tuberías
Biotest Aktiengesellschaft, a German biopharmaceutical company, develops and markets biological and biotechnological products, focusing on clinical immunology, haematology, and intensive care. With a global presence and a diverse product portfolio, Biotest addresses critical needs in specialized therapeutic areas, operating as a subsidiary of Grifols Biotest Holdings GmbH.
Tesis de Inversión
Biotest Aktiengesellschaft, with a market capitalization of $1.60 billion, presents a complex investment case. The company's focus on specialized therapeutic areas like immunology and haematology offers growth potential, particularly through its licensing agreement with Grifols. However, a negative profit margin of -3.9% and ROE of -4.7% raise concerns about profitability. The high debt-to-equity ratio of 131.22 indicates significant leverage. Upcoming catalysts include potential expansion of its product portfolio and increased market penetration through its partnership with Grifols. Potential risks include ongoing operational losses and the competitive nature of the biopharmaceutical industry.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $1.60B reflects Biotest's valuation in the biopharmaceutical sector.
- Negative Profit Margin of -3.9% indicates ongoing challenges in achieving profitability.
- Gross Margin of 23.2% suggests potential for improvement in production and sales efficiency.
- Debt-to-Equity Ratio of 131.22 indicates a highly leveraged capital structure.
- Free Cash Flow of $-0.00B reflects the company's current inability to generate positive cash flow.
Competidores y Pares
Fortalezas
- Specialized product portfolio in immunology and haematology.
- Established presence in Germany.
- Partnership with Grifols for manufacturing and marketing.
- Expertise in biological and biotechnological pharmaceutical products.
Debilidades
- Negative profit margin and ROE.
- High debt-to-equity ratio.
- Dependence on a limited number of key products.
- Limited geographic diversification.
Catalizadores
- Ongoing: Potential for increased revenue through the Grifols partnership.
- Upcoming: Expansion of product portfolio through R&D initiatives.
- Upcoming: Geographic expansion into emerging markets.
- Ongoing: Development of new therapies for clinical immunology and haematology.
Riesgos
- Ongoing: Negative profit margin and ROE.
- Ongoing: High debt-to-equity ratio.
- Potential: Intense competition from major pharmaceutical companies.
- Potential: Stringent regulatory requirements and approval processes.
- Potential: Limited liquidity due to OTC market trading.
Oportunidades de crecimiento
- Expansion of Product Portfolio: Biotest has the opportunity to expand its product portfolio through internal research and development, as well as strategic acquisitions or licensing agreements. Focusing on innovative therapies in clinical immunology, haematology, and intensive care medicine can drive revenue growth. The global market for immunomodulatory drugs is projected to reach $124.7 billion by 2027, presenting a significant opportunity for Biotest. Timeline: Ongoing.
- Increased Market Penetration through Grifols Partnership: The technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin provides Biotest with access to Grifols' global distribution network. This partnership can significantly increase market penetration and sales volume for these key products. The global market for plasma-derived therapies is expected to grow, driven by increasing demand for specialized treatments. Timeline: Ongoing.
- Geographic Expansion: Biotest can pursue geographic expansion into new markets, particularly in emerging economies with growing healthcare expenditures. Expanding its presence in regions with unmet medical needs can drive revenue growth and diversify its revenue streams. The emerging markets pharmaceutical sector is expected to grow significantly, offering substantial opportunities for Biotest. Timeline: 3-5 years.
- Strategic Acquisitions: Biotest could pursue strategic acquisitions of smaller biotechnology companies with complementary technologies or product pipelines. Acquiring innovative therapies or technologies can enhance Biotest's product portfolio and strengthen its competitive position. The market for mergers and acquisitions in the biopharmaceutical industry remains active, providing opportunities for strategic growth. Timeline: 2-3 years.
- Development of Biosimilars: Biotest can invest in the development of biosimilars, which are follow-on versions of existing biologic drugs. Biosimilars offer a lower-cost alternative to branded biologics and can capture a significant share of the market. The global biosimilars market is projected to reach $35.7 billion by 2025, presenting a substantial opportunity for Biotest. Timeline: 5+ years.
Oportunidades
- Expansion of product portfolio through R&D and acquisitions.
- Increased market penetration through Grifols partnership.
- Geographic expansion into emerging markets.
- Development of biosimilars.
Amenazas
- Intense competition from major pharmaceutical companies.
- Stringent regulatory requirements and approval processes.
- Risk of product liability claims.
- Potential for generic erosion of key products.
Ventajas competitivas
- Specialized product portfolio in niche therapeutic areas.
- Technology transfer and licensing agreement with Grifols, S.A.
- Established presence in the German biopharmaceutical market.
- Expertise in developing and manufacturing biological pharmaceutical products.
Acerca de BTTAY
Biotest Aktiengesellschaft, founded in 1946 and headquartered in Dreieich, Germany, is a biopharmaceutical company specializing in biological and biotechnological pharmaceutical products. Originally named Biotest Serum-Institut GmbH, the company changed its name in 1986 to Biotest Aktiengesellschaft. The company focuses on the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its product portfolio includes treatments for haemophilia A and B, cytomegalovirus infection, hepatitis B, primary and secondary antibody deficiency syndromes, autoimmune diseases, varicella zoster virus infections, and hepatitis B reinfection following liver transplantation. Key products include Haemoctin SDH and Vihuma for haemophilia A, Haemonine for haemophilia B, Cytotect CP biotest for cytomegalovirus, Fovepta and Hepatect CP for hepatitis B, and Intratect and Yimmugo for antibody deficiency syndromes and autoimmune diseases. Additionally, Biotest offers Albiomin and Biseco for blood volume restoration, Cofact for coagulation factor deficiency, Fibrinogen for fibrinogen deficiency, Trimodulin for community-acquired pneumonia, and Pentaglobin for bacterial infections. Biotest has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin, expanding its global reach and market presence. As a subsidiary of Grifols Biotest Holdings GmbH, Biotest leverages its parent company's resources and expertise to further its research, development, and commercialization efforts.
Qué hacen
- Develops biological pharmaceutical products.
- Manufactures biological pharmaceutical products.
- Sells biological pharmaceutical products in Germany and internationally.
- Specializes in clinical immunology therapies.
- Focuses on haematology treatments.
- Provides intensive care medicine solutions.
- Offers therapies for haemophilia A and B.
- Develops treatments for autoimmune diseases.
Modelo de Negocio
- Develops and manufactures biological and biotechnological pharmaceutical products.
- Sells products directly and through partnerships in Germany and internationally.
- Generates revenue through the sale of specialized therapies for clinical immunology, haematology, and intensive care medicine.
- Utilizes technology transfer and licensing agreements to expand market reach.
Contexto de la Industria
Biotest Aktiengesellschaft operates in the biopharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The global pharmaceuticals market is projected to reach trillions of dollars by 2026, driven by an aging population and increasing prevalence of chronic diseases. Biotest's focus on specialized therapeutic areas like immunology and haematology positions it within niche segments of this market. Competitors include major pharmaceutical companies and specialized biotech firms. The company's partnership with Grifols provides a competitive advantage through expanded market access and shared resources.
Clientes Clave
- Hospitals and clinics requiring specialized therapies.
- Patients with haemophilia A and B.
- Individuals with cytomegalovirus infection.
- Patients with hepatitis B.
- Individuals with primary and secondary antibody deficiency syndromes.
Finanzas
Gráfico e información
Precio de la acción de Biotest AG (BTTAY): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BTTAY.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BTTAY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BTTAY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BTTAY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Información de ADR de Biotest AG No patrocinado
Biotest AG (BTTAY) cotiza en los EE. UU. como un recibo de depósito estadounidense (ADR).
- Nivel de ADR: 1
- Ratio de ADR: 1:1
- Ticker del mercado local: BTTA
Información del mercado OTC de BTTAY
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biotest Aktiengesellschaft may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with limited operating history or those facing financial challenges.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and regulatory oversight.
- Potential for price volatility due to low trading volume.
- Higher risk of fraud or manipulation compared to major exchanges.
- Limited access to company information and management.
- Potential for delisting or suspension of trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's debt levels and cash flow.
- Check for any regulatory actions or legal proceedings against the company.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Established operating history since 1946.
- Subsidiary of Grifols Biotest Holdings GmbH.
- Partnership with Grifols, S.A.
- Focus on specialized therapeutic areas with unmet medical needs.
Preguntas Comunes Sobre BTTAY
¿Cuáles son los factores clave para evaluar BTTAY?
Biotest AG (BTTAY) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Specialized product portfolio in immunology and haematology.. Riesgo principal a monitorear: Ongoing: Negative profit margin and ROE.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BTTAY?
BTTAY actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BTTAY?
Los precios de BTTAY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BTTAY?
La cobertura de analistas para BTTAY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BTTAY?
Las categorías de riesgo para BTTAY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Negative profit margin and ROE.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BTTAY?
La relación P/E para BTTAY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BTTAY sobrevalorada o infravalorada?
Determinar si Biotest AG (BTTAY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BTTAY?
Biotest AG (BTTAY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is based on available information and may be subject to change.
- OTC market data may be limited or unreliable.
- AI analysis is pending and may provide further insights.